Author Correction: A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab

Author Correction: A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab

Show other versions (1)

Bibliographic Details
Main Authors:	Kiyomi Kuba, Hitoshi Inoue, Satoko Matsumura, Yuichiro Enoki, Yasunao Kogashiwa, Yasuhiro Ebihara, Mitsuhiko Nakahira, Tomoko Yamazaki, Masanari Yasuda, Kyoichi Kaira, Hiroshi Kagamu, Masashi Sugasawa
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-01-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-023-28598-w

Similar Items

A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab
by: Kiyomi Kuba, et al.
Published: (2022-12-01)

Author Correction: A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab
by: Kiyomi Kuba, et al.
Published: (2023-05-01)

Follicular adenoma with a papillary architecture originating from an ectopic thyroid gland: a case report
by: Kiyomi Kuba, et al.
Published: (2024-01-01)

Identification of novel oncogenes in oral cancer among elderly nonsmokers
by: Hitoshi Inoue, et al.
Published: (2023-08-01)

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
by: Kyoichi Kaira, et al.
Published: (2021-03-01)

Advanced Research on Immune Checkpoint Inhibitor Therapy
by: Hisao Imai, et al.
Published: (2022-09-01)

Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab
by: Atsuto Mouri, et al.
Published: (2024-04-01)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
by: Ayako Shiono, et al.
Published: (2019-04-01)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
by: Ou Yamaguchi, et al.
Published: (2019-04-01)

Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma
by: Kyoichi Kaira, et al.
Published: (2021-10-01)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
by: Kyoichi Kaira, et al.
Published: (2021-11-01)

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
by: Atsuto Mouri, et al.
Published: (2019-04-01)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR‐major mutant NSCLC receiving osimertinib
by: Kyoichi Kaira, et al.
Published: (2023-10-01)

Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
by: Kyoichi Kaira, et al.
Published: (2023-01-01)

A case of readministration of nivolumab by treating with apremilast for psoriasiform eruption as irAE
by: Naohisa Ichiki, et al.
Published: (2021-06-01)

Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment
by: Noboru Oriuchi, et al.
Published: (2022-08-01)

Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1
by: Ou Yamaguchi, et al.
Published: (2022-12-01)

Bullous pemphigoid in a metastatic lung cancer patient associated with nivolumab
by: Yuka Maya, MD, et al.
Published: (2020-12-01)

Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs
by: Atsuto Mouri, et al.
Published: (2021-08-01)

Improving visual acuity with nivolumab plus ipilimumab plus two cycles of chemotherapy following a diagnosis of lung adenocarcinoma with choroidal metastasis: A case report and literature review
by: Takahiro Matsuyama, et al.
Published: (2024-01-01)

Nivolumab for malignant transformation of ovarian mature cystic teratoma
by: Kayoko Yoshimura, et al.
Published: (2022-12-01)

Molecular Farming of Pembrolizumab and Nivolumab
by: Michael C. Stark, et al.
Published: (2023-06-01)

NIVOLUMAB EXPERIENCE IN PEDIATRIC MALIGNITIES
by: Melek YAMAN ORTAKOYLU, et al.
Published: (2022-10-01)

Photosensitive rash induced by nivolumab
by: Francisco J. Navarro-Triviño, et al.
Published: (2022-09-01)

Simple method for evaluating achievement degree of lung dose optimization in individual patients with locally advanced non‐small cell lung cancer treated with intensity modulated radiotherapy
by: Takanori Abe, et al.
Published: (2022-10-01)

Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
by: Takahiro Uchida, et al.
Published: (2019-04-01)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
by: Gillianne G.Y. Lai, MBBS, et al.
Published: (2022-12-01)

Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L)
by: Yuichi Ozawa, et al.
Published: (2024-01-01)

Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study
by: Hisao Imai, et al.
Published: (2021-12-01)

Umbilical lichen planus induced by nivolumab
by: Luisa Martos-Cabrera, et al.
Published: (2023-08-01)

Nivolumab in real-life clinical practice
by: M. A. Lyadova, et al.
Published: (2019-12-01)

Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status
by: Yuichi Adachi, et al.
Published: (2020-02-01)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
by: Liudmila Fedorova, et al.
Published: (2022-10-01)

1268 Eruptive keratoacanthomas secondary to nivolumab therapy
by: Eric Olsen, et al.
Published: (2023-11-01)

Effective treatment of gallbladder neuroendocrine carcinoma with nivolumab
by: Shinichiro Kanda, et al.
Published: (2023-10-01)

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma
by: M. N. Khagazheeva, et al.
Published: (2022-06-01)

Low-dose nivolumab in advanced hepatocellular carcinoma
by: Yen-Hao Chen, et al.
Published: (2022-11-01)

Urticaria multiforme following nivolumab-ipilimumab therapy
by: Sonal Muzumdar, et al.
Published: (2020-06-01)

Development of three endocrinopathies under nivolumab therapy
by: Anastasia A. Glibka, et al.
Published: (2023-02-01)

Case Report: Nivolumab-Induced Autoimmune Pancreatitis
by: Preeya Goyal, et al.
Published: (2021-11-01)